Antisense Therapeutics says dosing has commenced in combination study

September 12, 2022 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

Antisense Therapeutics (ASX:ANP) has commenced dosing in a muscular dystrophy mouse model of Duchenne muscular dystrophy to assess the potential clinical utility of ATL1102 in combination with dystrophin restoration drugs. …

Subscribe now to continue reading.

Latest Video

Georgia Forrest

BPDInsights.ai has arrived as a new way to access knowledge
March 9, 2026 - Latest News
Mark Butler steps in to block eye injection funding change after patient warnings
March 10, 2026 - Latest News
Pharmac says new agreement has improved access to treatment for New Zealanders
March 10, 2026 - Latest News
Labor’s FoI backdown is a welcome victory for transparency and accountability
March 10, 2026 - Latest News
There is an ideology behind our funding systems, and it's the greatest barrier to change
March 11, 2026 - Latest News

Antisense Therapeutics says dosing has commenced in combination study

This is a preview of subscriber content

Latest Video

Most Read

BPDInsights.ai has arrived as a new way to access knowledge

Mark Butler steps in to block eye injection funding change after patient warnings

Pharmac says new agreement has improved access to treatment for New Zealanders

Labor’s FoI backdown is a welcome victory for transparency and accountability

There is an ideology behind our funding systems, and it's the greatest barrier to change

New Stories

There is an ideology behind our funding systems, and it's the greatest barrier to change

New patient-led tool launched in Canberra to transform pain communication

Leader appointed to drive landmark Sydney biomedical hub toward global health breakthroughs

New digital partnership expands access to clinical guidance for Australian healthcare professionals

Self injection option offers new flexibility for Australians living with Myasthenia Gravis

CSL expands US manufacturing with $1.5bn investment to boost plasma therapy production

Labor’s FoI backdown is a welcome victory for transparency and accountability

Sign In

Antisense Therapeutics says dosing has commenced in combination study

This is a preview of subscriber content

Latest Video

Most Read

BPDInsights.ai has arrived as a new way to access knowledge

Mark Butler steps in to block eye injection funding change after patient warnings

Pharmac says new agreement has improved access to treatment for New Zealanders

Labor’s FoI backdown is a welcome victory for transparency and accountability

There is an ideology behind our funding systems, and it's the greatest barrier to change

Follow Us

New Stories

There is an ideology behind our funding systems, and it's the greatest barrier to change

New patient-led tool launched in Canberra to transform pain communication

Leader appointed to drive landmark Sydney biomedical hub toward global health breakthroughs

New digital partnership expands access to clinical guidance for Australian healthcare professionals

Self injection option offers new flexibility for Australians living with Myasthenia Gravis

CSL expands US manufacturing with $1.5bn investment to boost plasma therapy production

Labor’s FoI backdown is a welcome victory for transparency and accountability